Intellia Therapeutics Q2 2026 Earnings: Revenue Misses $7.7 Million
Intellia Therapeutics (Nasdaq: NTLA) reported Q2 2026 EPS of -$0.80, in line with consensus, but collaboration revenue fell to $7.7 million versus an estimated ~$13.0 million. Net loss was $106.6 million. The company said Phase 3 HAELO data for lonvo-z reduced attacks by 87% and expects lonvo-z BLA acceptance in H2 2026 and a U.S. launch in H1 2027. Cash was $628.4 million.
How this was made
The 30-second read
Why it matters
The quarter is a mixed fundamental update: collaboration revenue undershot expectations, but management emphasized lonvo-z Phase 3 validation and reiterated a conservative cash runway into 2028 while targeting FDA BLA acceptance in H2 2026.
Market read
Traders likely re-priced the balance between near-term partnership revenue weakness and the probability-weighted path to lonvo-z regulatory milestones, consistent with the stock’s reversal from premarket weakness to after-hours gains.
What to watch
EPS improvement was influenced by higher share count (dilution), and other income weakened as interest income declined, both of which can matter for valuation even if EPS is in-line.
Background
Intellia is a clinical-stage CRISPR gene-editing company with lonvo-z (HAE) as its key near-term regulatory catalyst and nex-z (ATTR amyloidosis) in enrollment.
Ticker impact
Intellia reported Q2 2026 EPS of -$0.80 in line, but collaboration revenue fell to $7.7M vs ~$13.0M, alongside lonvo-z Phase 3 and BLA timing guidance.
Near-term volatility likely driven by the revenue miss versus continued buy-side focus on lonvo-z regulatory milestones and cash runway into 2028.
The article provides concrete financial datapoints (collaboration revenue miss, EPS in-line, cash runway) and specific clinical/regulatory catalysts (HAELO 87% attack reduction; BLA acceptance window), and notes a reversal from premarket weakness to after-hours strength.
Market effects
Highlights how gene-editing biotechs can see earnings revenue misses discounted when clinical Phase 3 readouts and near-term regulatory timelines remain intact.
Limited, primarily impacts U.S. Nasdaq-listed biotech sentiment.
Low; the catalysts are company-specific (lonvo-z BLA acceptance and potential U.S. launch).
Counterpoint
The revenue miss and rising G&A could be an early signal that partnership economics are deteriorating, and the stock may be over-discounting future lonvo-z execution risk.
Key entities
- companyIntellia Therapeutics
Reported Q2 2026 results with a collaboration revenue miss, EPS in-line, and reiterated lonvo-z BLA acceptance and launch timing.
- pipeline_programlonvoguran ziclumeran (lonvo-z)
Phase 3 HAELO data reduced HAE attacks by 87% vs placebo; BLA acceptance expected in H2 2026.
- partnerRegeneron
Collaboration revenue decline is attributed largely to lower Regeneron revenue.
